Video
Dr. Stratton discusses combo of avelumab and BCG in NMIBC
Author(s):
Video Player is loading.
In this video, Kelly L. Stratton, MD, discusses further research on the study, “Novel weekly immunotherapy dosing with avelumab tolerated during Bacillus Calmette-Guerin induction therapy: Initial results of the ABD trial,” presented at the 2021 American Urological Association Annual Meeting, and his take on the current state of BCG-unresponsive non–muscle-invasive bladder cancer. Stratton is an assistant professor of urologic oncology at the University of Oklahoma, Oklahoma City.
Related Videos
5 key trial insights from AUA 2025
Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC
Khurshid Ghani, MD, on trial of stent omission following ureteroscopy
Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
Kevin Zorn, MD, on preserving ejaculation with BPH therapies
Neal Shore, MD, on sasanlimab plus BCG for BCG-naïve NMIBC
Alexander Glaser, MD, on real-world outcomes with Aquablation
Vitaly Margulis, MD, on preliminary safety, efficacy of padeliporfin VTP for UTUC
Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
Related Content
